Question explored with the scientific record
Are typhoid and hepatitis travel shots effective?
The evidence for typhoid and hepatitis travel vaccines is mixed: they raise antibodies, but the link to preventing actual infection in travelers is weaker than advertised.
The best typhoid data comes from a 2017 controlled human infection trial, where the Vi-tetanus toxoid conjugate vaccine showed 54.6% efficacy against developing typhoid fever after a deliberate challenge [1]. That is a real clinical endpoint, but it was measured in a lab, not on a trip to an endemic area. The older oral Ty21a vaccine had a compliance problem: one study found only 79% of travelers took all doses correctly, which cuts real-world effectiveness further [7]. The Vi polysaccharide version, often used for travel, had similar antibody responses when given alongside hepatitis A vaccine [6], but antibody levels are a surrogate, not proof of protection.
For hepatitis A, the evidence is mostly about population-level declines, not individual traveler protection. A large Chinese study covering 2004–2016 found that after routine childhood vaccination, hepatitis A incidence dropped by about 78–82% across all ages [4]. That is a population effect, not a traveler trial. The combined hepatitis A and typhoid vaccine (Vivaxim) was studied in 425 Australian children and found no serious adverse events, but the follow-up was only 3 days and there was no control group [8]. That tells you about short-term side effects, not whether it prevented disease on a trip.
The hepatitis B vaccine data is even more distant from the travel question. The retrieved studies focus on infant immunization in Taiwan reducing liver cancer decades later [2], and on healthcare worker protection [3, 5]. Neither tests a traveler's risk of acute hepatitis B infection during a short trip.
| Vaccine | What was measured | Result | Real-world travel protection? |
|---|---|---|---|
| Typhoid Vi-TT | Infection after deliberate challenge | 54.6% efficacy [1] | Plausible but unconfirmed in travelers |
| Typhoid oral Ty21a | Compliance with 4-dose schedule | 79% took all doses [7] | Lower if doses missed |
| Hepatitis A (China program) | Population incidence decline | 78–82% drop [4] | Not tested in travelers |
| Combined HAV + typhoid (Vivaxim) | Short-term side effects in children | No serious AEs, 70% sore arm [8] | No efficacy data |
The missing piece is a head-to-head trial comparing vaccinated versus unvaccinated travelers, tracking actual infection rates. That study has not been retrieved here. Without it, you are relying on antibody surrogates and population trends, not direct proof that the shot prevents illness on your trip.
My call: These vaccines likely reduce your risk of typhoid and hepatitis A, but the evidence is built on surrogate endpoints and population studies, not on traveler-specific trials. The benefit is modest and the real-world effectiveness is uncertain. Confidence: low for traveler-specific protection.
Sources used 8
-
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
This study demonstrates that the Vi-tetanus toxoid conjugate vaccine significantly reduces the incidence of typhoid fever in a controlled human infection model, showing an efficacy of 54.6% compared to a control vaccine.
DOI: 10.1016/S0140-6736(17)32149-9 -
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
This study investigates the long-term effects of hepatitis B immunization in infants on the incidence of hepatocellular carcinoma (HCC) in Taiwan, demonstrating a significant reduction in HCC risk among vaccinated individuals compared to unvaccinated cohorts.
DOI: 10.1053/j.gastro.2016.05.048 -
Understanding viral hepatitis B
This paper discusses the history, transmission, and prevention of viral hepatitis B, emphasizing its significance as an occupational hazard for healthcare workers and the importance of vaccination.
DOI: 10.1016/s1084-628x(97)90065-4 -
The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004–2016
This study evaluates the impact of the expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China from 2004 to 2016, finding a significant decline in HepA incidence across all age groups with high vaccination coverage.
DOI: 10.1016/j.vaccine.2018.01.043 -
Vaccination against hepatitis B in health care workers
This study examines the prevalence of hepatitis B virus (HBV) infection among healthcare workers, the effectiveness of vaccination, and the need for improved vaccination coverage and new vaccine development to protect this high-risk population.
DOI: 10.1016/s0264-410x(00)00460-6 -
Concomitant Vaccination against Hepatitis A and Typhoid Fever
This study evaluates the safety, reactogenicity, and immunogenicity of administering a hepatitis A vaccine (Havrix-1440TM) simultaneously with a Vi polysaccharide typhoid vaccine in healthy adults, finding that both vaccines can be safely co-administered without adverse effects …
DOI: 10.1111/j.1708-8305.1998.tb00483.x -
Compliance with oral typhoid vaccine Ty21a in travellers
This study assesses the compliance of travellers with the oral typhoid vaccine Ty21a, finding that 79.1% of participants adhered to the vaccination schedule despite its complexity.
DOI: 10.1016/s1576-9887(03)70312-4 -
The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2–16 years: an observational study
This prospective observational study in Australian travel clinics assessed the tolerability of the combined hepatitis A and typhoid vaccine (Vivaxim) in children aged 2–16 years, finding no serious adverse events, higher local reactogenicity than monovalent vaccines, and general…
DOI: 10.1093/jtm/tav023